Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for extended prophylaxis in colorectal cancer surgery
NCT03055026Phase 3Completed
- Sponsor
- Fondazione FADOI
- Start
- May 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE) comparing Rivaroxaban with Placebo (2 arms). Primary endpoint: Venous Thromboembolism at 28 days. Started May 2017; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03055026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055026.